IJC:月经不规则可能增加卵巢癌风险?

2016-04-28 佚名 生物谷

        最近一项研究表明,月经周期紊乱的女性晚年发生卵巢癌以及因卵巢癌死亡的风险更高。这项研究首次表明女性月经周期在非正常情况下变长或无月经与卵巢癌风险增加之间存在关联,同时对之前关于随着女性排卵总数增加,卵巢癌风险也逐渐增加的假说提出了挑战。 相关研究结果发表在国际学术期刊International Journal of Cancer上。

       

最近一项研究表明,月经周期紊乱的女性晚年发生卵巢癌以及因卵巢癌死亡的风险更高。这项研究首次表明女性月经周期在非正常情况下变长或无月经与卵巢癌风险增加之间存在关联,同时对之前关于随着女性排卵总数增加,卵巢癌风险也逐渐增加的假说提出了挑战。

相关研究结果发表在国际学术期刊International Journal of Cancer上。

普遍认为排卵周期少是避免卵巢癌的一种保护性因素。因此服用特定类型的避孕药,妊娠以及输卵管结扎等终止排卵的措施也被认为能够帮助降低卵巢癌风险。

虽然在所有患癌女性中,卵巢癌患者仅占3%,但卵巢癌是所有妇科癌症中的头号杀手。所有诊断为卵巢癌的女性中只有不到一半的病人存活超过5年。一些卵巢癌的早期症状经常被病人忽视或被误诊为其他疾病,并且目前还没有用于卵巢癌常规筛查的方法和标记物,因此多数病人发现病情的时候已经错过最佳治疗时机。

为了找到除年龄和遗传之外的风险因素,流行病学家Barbara Cohn以及她带领的研究团队对1959年一项关于女性妊娠的大型研究的数据进行了深入分析,该研究包含了来自美国加州的超过15000名女性。研究人员期望能够对母女在一生中罹患卵巢癌的风险进行追踪。在这项大型研究刚开始的时候即有大约13%的女性存在月经周期紊乱的情况(一个月经周期的时间超过35天或者长期出现月经周期少或无经),当时参与研究的女性平均年龄为26岁。

在接下来的50年中,有116名女性患卵巢癌,其中84人死于卵巢癌。到参与者70岁的时候,有月经周期紊乱情况的女性罹患卵巢癌以及死于卵巢癌的风险接近正常女性的两倍,这种关联性只随年龄增长而变强。举例来说,到女性年龄达到77岁的时候,有月经周期紊乱情况的女性罹患卵巢癌以及死于卵巢癌的风险大约是正常女性的三倍。

这些卵巢癌患者中许多人同时存在多囊卵巢综合征(PCOS),而PCOS患者经常存在月经周期紊乱或无经的情况,研究人员认为PCOS可能是促进卵巢癌发生的一个重要原因,但由于PCOS的诊断标准出现在该研究开始以后,因此无法根据这项研究的结果得出两者之间的确切关系。

研究人员表示,这项研究的结果对未来研究有一些指导意义,不仅能够帮助发现卵巢癌高风险人群还可以告诉人们哪些女性能够通过筛查或预防措施受益。

原始出处:

Cirillo PM, Wang ET, Cedars MI, Chen LM, Cohn BA. Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies. Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30144

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=139339, encodeId=6c75139339fb, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:29:47 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061525, encodeId=c7aa2061525f3, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Mar 01 23:15:00 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84198, encodeId=dd78841981a, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 04 14:48:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376777, encodeId=07e813e677778, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Apr 30 05:15:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83298, encodeId=be9983298a4, content=学习了,卵巢癌现在也多发, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Fri Apr 29 14:28:00 CST 2016, time=2016-04-29, status=1, ipAttribution=)]
    2016-10-03 1e10c84am36(暂无匿称)

    深度好文,值得关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=139339, encodeId=6c75139339fb, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:29:47 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061525, encodeId=c7aa2061525f3, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Mar 01 23:15:00 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84198, encodeId=dd78841981a, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 04 14:48:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376777, encodeId=07e813e677778, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Apr 30 05:15:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83298, encodeId=be9983298a4, content=学习了,卵巢癌现在也多发, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Fri Apr 29 14:28:00 CST 2016, time=2016-04-29, status=1, ipAttribution=)]
    2017-03-01 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=139339, encodeId=6c75139339fb, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:29:47 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061525, encodeId=c7aa2061525f3, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Mar 01 23:15:00 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84198, encodeId=dd78841981a, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 04 14:48:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376777, encodeId=07e813e677778, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Apr 30 05:15:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83298, encodeId=be9983298a4, content=学习了,卵巢癌现在也多发, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Fri Apr 29 14:28:00 CST 2016, time=2016-04-29, status=1, ipAttribution=)]
    2016-05-04 1dd8c52fm63(暂无匿称)

    学习啦!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=139339, encodeId=6c75139339fb, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:29:47 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061525, encodeId=c7aa2061525f3, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Mar 01 23:15:00 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84198, encodeId=dd78841981a, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 04 14:48:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376777, encodeId=07e813e677778, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Apr 30 05:15:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83298, encodeId=be9983298a4, content=学习了,卵巢癌现在也多发, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Fri Apr 29 14:28:00 CST 2016, time=2016-04-29, status=1, ipAttribution=)]
    2016-04-30 luwei00
  5. [GetPortalCommentsPageByObjectIdResponse(id=139339, encodeId=6c75139339fb, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:29:47 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061525, encodeId=c7aa2061525f3, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Mar 01 23:15:00 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84198, encodeId=dd78841981a, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 04 14:48:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376777, encodeId=07e813e677778, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sat Apr 30 05:15:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83298, encodeId=be9983298a4, content=学习了,卵巢癌现在也多发, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Fri Apr 29 14:28:00 CST 2016, time=2016-04-29, status=1, ipAttribution=)]
    2016-04-29 明崖

    学习了,卵巢癌现在也多发

    0

相关资讯

JCO:卵巢癌新药Farletuzumab三期临床试验结果发表,3年前已完成试验,结果阴性

 Farletuzumab是一种人源化的单克隆抗体,其靶点为叶酸受体α。叶酸受体α在卵巢癌中高度表达而在大部分正常组织中并不存在。Farletuzumab目前处于双盲、随机的三期临床试验中,用于治疗对铂敏感性卵巢癌。 符合试验条件的患者是在经过铂-紫杉烷化疗完成后出现首次复发6-24个月。所以的患者均接受卡铂加紫杉醇或者多系紫杉醇(六个循环结合随机分配的测试药物,比例为1:1:

NEJM:服用紫杉醇的频率(每周一次 vs 每3周一次)对于治疗卵巢癌无显著效果差异

每周计划密集剂量的紫杉醇(导致药物递送的一个更大的频率),加上每3周给予卡铂或在紫杉醇中加入贝伐单抗和每3周施用卡铂治疗卵巢癌已显示出功效。研究人员旨在确定再那些接受和没有接受贝伐单抗的患者中,每周密集剂量的紫杉醇和卡铂与每3周接受紫杉醇和卡铂相比,是否会延长无进展生存期。原始出处:John K. Chan,Mark F. Brady,Richard T. Penson,et al.Weekly

卵巢癌化疗和靶向治疗相关进展---美国妇科肿瘤学会(SGO)年会记录

美国妇科肿瘤学会(SGO)年会于2016年3月18-22日在圣迭戈召开。作为女性生殖系统3大肿瘤之一,卵巢癌的诊治成为本次会议讨论热点话题。卵巢癌早期诊断困难,死亡率高,近30年在诊治投入产出方面无突破性进展,晚期卵巢癌5年生存率无明显提高,治疗仍是铂类为基础的化疗为主。随着多聚二磷酸腺苷核糖聚合酶(PARP)抑制剂奥拉帕尼(olaparib)在2014年12月被美国食品与药物管理局(FDA)

国内多中心研究发表:中国健康人群HE4参考值确立

ElecsysRHE4多中心研究发表 中国健康人群HE4参考值确立 ■高莹莹 血清肿瘤标志物人附睾蛋白4(HE4)在卵巢癌早期诊断、治疗监测及预后评估中具有重要医学价值,临床应用日益广泛。但临床中,试剂说明书提供的参考范围源于国外人群研究,其正常参考值与中国人群临床所见存在一定差距,给临床诊疗带来一定困难。因此,使用大规模HE4临床实验数据,按照年龄段或绝经前、后区分参考值,为临

NEJM:高危人群预防性切除乳腺、卵巢,是对或是错?

本月发表在新英国医学杂志上的文章对还未患上癌症的遗传性乳腺癌和卵巢癌综合征人群的相关的问题进行了探讨。文章讨论了乳腺癌和卵巢癌最佳的风险评估、风险降低手术的实用性、这些操作的副作用、预防癌症的替代策略和决策的最佳方法。梅奥诊所的肿瘤学家Lynn Hartmann博士,也是本文作者,他说:“遗传性乳腺癌和卵巢癌综合征女性的癌症风险高于一般人群,虽然预防性切除乳腺、输卵管和卵巢,可以降低癌症风险,但切

Eur J Cancer:主观评价VS超声模型诊断卵巢癌:meta分析

介绍:目前许多国家指南关于卵巢癌的管理提倡使用恶性肿瘤风险指数(RMI)来描述卵巢的病理。然而,其他的方法,如主观评价,国际卵巢癌分析(IOTA)基于超声的标准(简易标准)和IOTA逻辑回归模型(LR2)似乎比RMI更好。我们的目的在于比较主观评价、简易标准、 LR2和RMI在术前评估不同来源的附件恶性肿块的诊断准确性。